AssetMark Inc’s Vaxcyte PCVX Stock Holding History

AssetMark Inc’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$189K	Buy	3,321 +1,470	+79%	+$85.7K	﹤0.01%	1478
2026 Q2	$108K	Sell	1,851 -28	-1%	-$1.52K	﹤0.01%	1604
2026 Q1	$109K	Sell	1,879 -16	-0.8%	-$869	﹤0.01%	1514
2025 Q4	$87.4K	Sell	1,895 -11,427	-86%	-$511K	﹤0.01%	1541
2025 Q3	$480K	Sell	13,322 -288	-2%	-$9.5K	﹤0.01%	1108
2025 Q2	$442K	Sell	13,610 -814	-6%	-$26.7K	﹤0.01%	1071
2025 Q1	$545K	Buy	14,424 +13,648	+1,759%	+$1.09M	﹤0.01%	965
2024 Q4	$63.5K	Buy	776 +775	+77,500%	+$77K	﹤0.01%	1356
2024 Q3	$114	Buy	+1	New	+$90	﹤0.01%	2199

Other funds holding PCVX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

AssetMark Inc's PCVX Position: Q3 2026 in Review

AssetMark Inc increased its Vaxcyte (PCVX) stake by 79% in Q3 2026, buying an estimated $85.7K and bringing the position to 3,321 shares worth $189K. The position accounts for ﹤0.01% of the portfolio, ranked #1478.

AssetMark Inc first reported a position in PCVX in Q3 2024 and has held it in 9 quarters since. The position peaked at $545K in Q1 2025. 127 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

AssetMark Inc held 3,321 shares of Vaxcyte worth $189K as of Q3 2026.
AssetMark Inc bought 1,470 Vaxcyte shares in Q3 2026, an estimated $85.7K.
Vaxcyte made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #1478 holding.
AssetMark Inc first reported a position in Vaxcyte in Q3 2024 and has held it in 9 quarters since.
AssetMark Inc's Vaxcyte position peaked at $545K in Q1 2025.
127 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.